GI effects such as appetite loss, nausea and diarrhoea are common with Esbriet as well as its main rival in the IPF market, Behringer Ingelheim's Ofev (nintedanib). In around 50% of cases ...
Ofev (nintedanib) has been recommended since ... It's main rival in the market – Roche's Esbriet (pirfenidone) – remains an option for patients with FVC in the 50% to 80% range only.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback